The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Oct. 08, 2013
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Universite DE Montpellier, Montpellier, FR;

Centre Hospitalier Universitaire DE Montpellier, Montpellier, FR;

Inventors:

Jerome Moreaux, Montpellier, FR;

Bernard Klein, Montpellier, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); C12Q 1/6886 (2018.01); A61K 31/165 (2006.01); A61K 31/185 (2006.01); A61K 31/19 (2006.01); A61K 31/4045 (2006.01); G06F 19/20 (2011.01); G06G 7/58 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/165 (2013.01); A61K 31/185 (2013.01); A61K 31/19 (2013.01); A61K 31/4045 (2013.01); G06F 19/20 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01);
Abstract

The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein βi represent the regression β coefficient reference value for the gene Gand Ci=1 if the expression of the gene G(ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASv) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASor concluding that the patient will not respond to the HDACi when the HAS score is lower than the predetermined value HAS.


Find Patent Forward Citations

Loading…